PROFILES - Connect with RTRN Researchers

Francis Eko
Title Res. Asst. Professor, Dept. of MBI
Faculty Rank
Degree Ph.D.
Institution Morehouse School of Medicine
Postal Code
Telephone 404-752-1584
QR Barcode

Narrative icon

Not Available

Publications icon

  Check NIH Public Access Policy Compliance

Please wait
1. Chu J, Li X, Qu G, Wang Y, Li Q, Guo Y, Hou L, Liu J, Eko FO, He C. Correction: Chlamydia psittaci PmpD-N modulated Chicken Macrophage Function by Triggering Th2 Polarization and the TLR2/MyD88/NF-?B Signaling Pathway. Int J Mol Sci. 2020 Apr 10; 21(7).
2. Igietseme JU, Partin J, George Z, Omosun Y, Goldstein J, Joseph K, Ellerson D, Eko FO, Pohl J, Bandea C, Black CM. Epidermal Growth Factor Receptor and Transforming Growth Factor ß Signaling Pathways Cooperate To Mediate Chlamydia Pathogenesis. Infect Immun. 2020 Mar 23; 88(4).
3. Chu J, Li X, Qu G, Wang Y, Li Q, Guo Y, Hou L, Liu J, Eko FO, He C. Chlamydia psittaci PmpD-N Exacerbated Chicken Macrophage Function by Triggering Th2 Polarization and the TLR2/MyD88/NF-?B Signaling Pathway. Int J Mol Sci. 2020 Mar 15; 21(6).
4. Lundy SR, Ahmad T, Simoneaux T, Benyeogor I, Robinson Y, George Z, Ellerson D, Kirlin W, Omosun T, Eko FO, Black CM, Blas-Machado U, DeBruyne JP, Igietseme JU, He Q, Omosun YO. Effect of Time of Day of Infection on Chlamydia Infectivity and Pathogenesis. Sci Rep. 2019 08 06; 9(1):11405.
5. Pais R, Omosun Y, Igietseme JU, Fujihashi K, Eko FO. Route of Vaccine Administration Influences the Impact of Fms-Like Tyrosine Kinase 3 Ligand (Flt3L) on Chlamydial-Specific Protective Immune Responses. Front Immunol. 2019; 10:1577.
6. Benyeogor I, Simoneaux T, Wu Y, Lundy S, George Z, Ryans K, McKeithen D, Pais R, Ellerson D, Lorenz WW, Omosun T, Thompson W, Eko FO, Black CM, Blas-Machado U, Igietseme JU, He Q, Omosun Y. A unique insight into the MiRNA profile during genital chlamydial infection. BMC Genomics. 2019 Feb 18; 20(1):143.
7. George Z, Omosun Y, Azenabor AA, Goldstein J, Partin J, Joseph K, Ellerson D, He Q, Eko F, McDonald MA, Reed M, Svoboda P, Stuchlik O, Pohl J, Lutter E, Bandea C, Black CM, Igietseme JU. The molecular mechanism of induction of unfolded protein response by Chlamydia. Biochem Biophys Res Commun. 2019 01 08; 508(2):421-429.
8. Igietseme JU, Omosun Y, Nagy T, Stuchlik O, Reed MS, He Q, Partin J, Joseph K, Ellerson D, George Z, Goldstein J, Eko FO, Bandea C, Pohl J, Black CM. Molecular Pathogenesis of Chlamydia Disease Complications: Epithelial-Mesenchymal Transition and Fibrosis. Infect Immun. 2018 01; 86(1).
9. Pan Q, Zhang Q, Chu J, Pais R, Liu S, He C, Eko FO. Chlamydia abortus Pmp18.1 Induces IL-1ß Secretion by TLR4 Activation through the MyD88, NF-?B, and Caspase-1 Signaling Pathways. Front Cell Infect Microbiol. 2017; 7:514.
10. McKeithen DN, Omosun YO, Ryans K, Mu J, Xie Z, Simoneaux T, Blas-Machado U, Eko FO, Black CM, Igietseme JU, He Q. The emerging role of ASC in dendritic cell metabolism during Chlamydia infection. PLoS One. 2017; 12(12):e0188643.
11. Pais R, Omosun Y, He Q, Blas-Machado U, Black C, Igietseme JU, Fujihashi K, Eko FO. Rectal administration of a chlamydial subunit vaccine protects against genital infection and upper reproductive tract pathology in mice. PLoS One. 2017; 12(6):e0178537.
12. Ryans K, Omosun Y, McKeithen DN, Simoneaux T, Mills CC, Bowen N, Eko FO, Black CM, Igietseme JU, He Q. The immunoregulatory role of alpha enolase in dendritic cell function during Chlamydia infection. BMC Immunol. 2017 05 19; 18(1):27.
13. George Z, Omosun Y, Azenabor AA, Partin J, Joseph K, Ellerson D, He Q, Eko F, Bandea C, Svoboda P, Pohl J, Black CM, Igietseme JU. The Roles of Unfolded Protein Response Pathways in Chlamydia Pathogenesis. J Infect Dis. 2017 02 01; 215(3):456-465.
14. Igietseme JU, Omosun Y, Stuchlik O, Reed MS, Partin J, He Q, Joseph K, Ellerson D, Bollweg B, George Z, Eko FO, Bandea C, Liu H, Yang G, Shieh WJ, Pohl J, Karem K, Black CM. Role of Epithelial-Mesenchyme Transition in Chlamydia Pathogenesis. PLoS One. 2015; 10(12):e0145198.
15. Omosun Y, McKeithen D, Ryans K, Kibakaya C, Blas-Machado U, Li D, Singh R, Inoue K, Xiong ZG, Eko F, Black C, Igietseme J, He Q. Interleukin-10 modulates antigen presentation by dendritic cells through regulation of NLRP3 inflammasome assembly during Chlamydia infection. Infect Immun. 2015 Dec; 83(12):4662-72.
16. Pan Q, Pais R, Ohandjo A, He C, He Q, Omosun Y, Igietseme JU, Eko FO. Comparative evaluation of the protective efficacy of two formulations of a recombinant Chlamydia abortus subunit candidate vaccine in a mouse model. Vaccine. 2015 Apr 08; 33(15):1865-72.
17. Eko FO, Mania-Pramanik J, Pais R, Pan Q, Okenu DM, Johnson A, Ibegbu C, He C, He Q, Russell R, Black CM, Igietseme JU. Vibrio cholerae ghosts (VCG) exert immunomodulatory effect on dendritic cells for enhanced antigen presentation and induction of protective immunity. BMC Immunol. 2014 Dec 31; 15:584.
18. Ou C, Tian D, Ling Y, Pan Q, He Q, Eko FO, He C. Evaluation of an ompA-based phage-mediated DNA vaccine against Chlamydia abortus in piglets. Int Immunopharmacol. 2013 Aug; 16(4):505-10.
19. Pokam BT, Asuquo AE, Abia-Bassey LN, Idasa MB, Umoh NO, Eko FO, Rastogi N. Multidrug resistance and demography of newly diagnosed tuberculosis patients in Cross River State, Nigeria. Int J Mycobacteriol. 2013 Jun; 2(2):89-93.
20. Igietseme JU, Omosun Y, Partin J, Goldstein J, He Q, Joseph K, Ellerson D, Ansari U, Eko FO, Bandea C, Zhong G, Black CM. Prevention of Chlamydia-induced infertility by inhibition of local caspase activity. J Infect Dis. 2013 Apr; 207(7):1095-104.
21. He Q, Ananaba GA, Patrickson J, Pitts S, Yi Y, Yan F, Eko FO, Lyn D, Black CM, Igietseme JU, Thierry-Palmer M. Chlamydial infection in vitamin D receptor knockout mice is more intense and prolonged than in wild-type mice. J Steroid Biochem Mol Biol. 2013 May; 135:7-14.
22. Igietseme JU, Eko FO, Black CM. Chlamydia vaccines: recent developments and the role of adjuvants in future formulations. Expert Rev Vaccines. 2011 Nov; 10(11):1585-96.
23. Thumamo BP, Asuquo AE, Abia-Bassey LN, Lawson L, Hill V, Zozio T, Emenyonu N, Eko FO, Rastogi N. Molecular epidemiology and genetic diversity of Mycobacterium tuberculosis complex in the Cross River State, Nigeria. Infect Genet Evol. 2012 Jun; 12(4):671-7.
24. Eko FO, Okenu DN, Singh UP, He Q, Black C, Igietseme JU. Evaluation of a broadly protective Chlamydia-cholera combination vaccine candidate. Vaccine. 2011 May 12; 29(21):3802-10.
25. Eko FO, Ekong E, He Q, Black CM, Igietseme JU. Induction of immune memory by a multisubunit chlamydial vaccine. Vaccine. 2011 Feb 04; 29(7):1472-80.
26. Eko FO, Talin BA, Lubitz W. Development of a Chlamydia trachomatis bacterial ghost vaccine to fight human blindness. Hum Vaccin. 2008 May-Jun; 4(3):176-83.
27. Igietseme JU, He Q, Joseph K, Eko FO, Lyn D, Ananaba G, Campbell A, Bandea C, Black CM. Role of T lymphocytes in the pathogenesis of Chlamydia disease. J Infect Dis. 2009 Sep 15; 200(6):926-34.
28. Ramey K, Eko FO, Thompson WE, Armah H, Igietseme JU, Stiles JK. Immunolocalization and challenge studies using a recombinant Vibrio cholerae ghost expressing Trypanosoma brucei Ca(2+) ATPase (TBCA2) antigen. Am J Trop Med Hyg. 2009 Sep; 81(3):407-15.
29. Ekong EE, Okenu DN, Mania-Pramanik J, He Q, Igietseme JU, Ananaba GA, Lyn D, Black C, Eko FO. A Vibrio cholerae ghost-based subunit vaccine induces cross-protective chlamydial immunity that is enhanced by CTA2B, the nontoxic derivative of cholera toxin. FEMS Immunol Med Microbiol. 2009 Mar; 55(2):280-91.
30. He Q, Eko FO, Lyn D, Ananaba GA, Bandea C, Martinez J, Joseph K, Kellar K, Black CM, Igietseme JU. Involvement of LEK1 in dendritic cell regulation of T cell immunity against Chlamydia. J Immunol. 2008 Sep 15; 181(6):4037-42.
31. Silva AJ, Eko FO, Benitez JA. Exploiting cholera vaccines as a versatile antigen delivery platform. Biotechnol Lett. 2008 Apr; 30(4):571-9.
32. Ifere GO, He Q, Igietseme JU, Ananaba GA, Lyn D, Lubitz W, Kellar KL, Black CM, Eko FO. Immunogenicity and protection against genital Chlamydia infection and its complications by a multisubunit candidate vaccine. J Microbiol Immunol Infect. 2007 Jun; 40(3):188-200.
33. He Q, Martinez-Sobrido L, Eko FO, Palese P, Garcia-Sastre A, Lyn D, Okenu D, Bandea C, Ananaba GA, Black CM, Igietseme JU. Live-attenuated influenza viruses as delivery vectors for Chlamydia vaccines. Immunology. 2007 Sep; 122(1):28-37.
34. Igietseme JU, Eko FO, He Q, Black CM. Combination vaccines: design strategies and future trends. Expert Rev Vaccines. 2006 Dec; 5(6):739-45.
35. Macmillan L, Ifere GO, He Q, Igietseme JU, Kellar KL, Okenu DM, Eko FO. A recombinant multivalent combination vaccine protects against Chlamydia and genital herpes. FEMS Immunol Med Microbiol. 2007 Feb; 49(1):46-55.
36. Barr EL, Ouburg S, Igietseme JU, Morré SA, Okwandu E, Eko FO, Ifere G, Belay T, He Q, Lyn D, Nwankwo G, Lillard JW, Black CM, Ananaba GA. Host inflammatory response and development of complications of Chlamydia trachomatis genital infection in CCR5-deficient mice and subfertile women with the CCR5delta32 gene deletion. J Microbiol Immunol Infect. 2005 Aug; 38(4):244-54.
37. Igietseme J, Eko F, He Q, Bandea C, Lubitz W, Garcia-Sastre A, Black C. Delivery of Chlamydia vaccines. Expert Opin Drug Deliv. 2005 May; 2(3):549-62.
38. He Q, Moore TT, Eko FO, Lyn D, Ananaba GA, Martin A, Singh S, James L, Stiles J, Black CM, Igietseme JU. Molecular basis for the potency of IL-10-deficient dendritic cells as a highly efficient APC system for activating Th1 response. J Immunol. 2005 Apr 15; 174(8):4860-9.
39. Walcher P, Mayr UB, Azimpour-Tabrizi C, Eko FO, Jechlinger W, Mayrhofer P, Alefantis T, Mujer CV, DelVecchio VG, Lubitz W. Antigen discovery and delivery of subunit vaccines by nonliving bacterial ghost vectors. Expert Rev Vaccines. 2004 Dec; 3(6):681-91.
40. Eko FO, He Q, Brown T, McMillan L, Ifere GO, Ananaba GA, Lyn D, Lubitz W, Kellar KL, Black CM, Igietseme JU. A novel recombinant multisubunit vaccine against Chlamydia. J Immunol. 2004 Sep 01; 173(5):3375-82.
41. Igietseme JU, Eko FO, He Q, Bandea C, Black CM. Developing effective delivery systems for Chlamydia vaccines. Curr Opin Mol Ther. 2004 Apr; 6(2):182-94.
42. Igietseme JU, Eko FO, He Q, Black CM. Antibody regulation of Tcell immunity: implications for vaccine strategies against intracellular pathogens. Expert Rev Vaccines. 2004 Feb; 3(1):23-34.
43. Eko FO, Schukovskaya T, Lotzmanova EY, Firstova VV, Emalyanova NV, Klueva SN, Kravtzov AL, Livanova LF, Kutyrev VV, Igietseme JU, Lubitz W. Evaluation of the protective efficacy of Vibrio cholerae ghost (VCG) candidate vaccines in rabbits. Vaccine. 2003 Sep 08; 21(25-26):3663-74.
44. Moore T, Ekworomadu CO, Eko FO, MacMillan L, Ramey K, Ananaba GA, Patrickson JW, Nagappan PR, Lyn D, Black CM, Igietseme JU. Fc receptor-mediated antibody regulation of T cell immunity against intracellular pathogens. J Infect Dis. 2003 Aug 15; 188(4):617-24.
45. Eko FO, Lubitz W, McMillan L, Ramey K, Moore TT, Ananaba GA, Lyn D, Black CM, Igietseme JU. Recombinant Vibrio cholerae ghosts as a delivery vehicle for vaccinating against Chlamydia trachomatis. Vaccine. 2003 Apr 02; 21(15):1694-703.
46. Jalava K, Eko FO, Riedmann E, Lubitz W. Bacterial ghosts as carrier and targeting systems for mucosal antigen delivery. Expert Rev Vaccines. 2003 Feb; 2(1):45-51.
47. Igietseme JU, Eko FO, Black CM. Contemporary approaches to designing and evaluating vaccines against Chlamydia. Expert Rev Vaccines. 2003 Feb; 2(1):129-46.
48. Belay T, Eko FO, Ananaba GA, Bowers S, Moore T, Lyn D, Igietseme JU. Chemokine and chemokine receptor dynamics during genital chlamydial infection. Infect Immun. 2002 Feb; 70(2):844-50.
49. Moore T, Ananaba GA, Bolier J, Bowers S, Belay T, Eko FO, Igietseme JU. Fc receptor regulation of protective immunity against Chlamydia trachomatis. Immunology. 2002 Feb; 105(2):213-21.
50. Eko FO, Mayr UB, Attridge SR, Lubitz W. Characterization and immunogenicity of Vibrio cholerae ghosts expressing toxin-coregulated pili. J Biotechnol. 2000 Sep 29; 83(1-2):115-23.
51. Igietseme JU, Ananaba GA, Bolier J, Bowers S, Moore T, Belay T, Eko FO, Lyn D, Black CM. Suppression of endogenous IL-10 gene expression in dendritic cells enhances antigen presentation for specific Th1 induction: potential for cellular vaccine development. J Immunol. 2000 Apr 15; 164(8):4212-9.
52. Lubitz W, Witte A, Eko FO, Kamal M, Jechlinger W, Brand E, Marchart J, Haidinger W, Huter V, Felnerova D, Stralis-Alves N, Lechleitner S, Melzer H, Szostak MP, Resch S, Mader H, Kuen B, Mayr B, Mayrhofer P, Geretschläger R, Haslberger A, Hensel A. Extended recombinant bacterial ghost system. J Biotechnol. 1999 Aug 20; 73(2-3):261-73.
53. Utsalo SJ, Eko FO, Umoh F, Asindi AA. Faecal excretion of Vibrio cholerae during convalescence of cholera patients in Calabar, Nigeria. Eur J Epidemiol. 1999 Apr; 15(4):379-81.
54. Eko FO, Witte A, Huter V, Kuen B, Fürst-Ladani S, Haslberger A, Katinger A, Hensel A, Szostak MP, Resch S, Mader H, Raza P, Brand E, Marchart J, Jechlinger W, Haidinger W, Lubitz W. New strategies for combination vaccines based on the extended recombinant bacterial ghost system. Vaccine. 1999 Mar 26; 17(13-14):1643-9.
55. Szostak MP, Mader H, Truppe M, Kamal M, Eko FO, Huter V, Marchart J, Jechlinger W, Haidinger W, Brand E, Denner E, Resch S, Dehlin E, Katinger A, Kuen B, Haslberger A, Hensel A, Lubitz W. Bacterial ghosts as multifunctional vaccine particles. Behring Inst Mitt. 1997 Feb; (98):191-6.
56. Szostak MP, Hensel A, Eko FO, Klein R, Auer T, Mader H, Haslberger A, Bunka S, Wanner G, Lubitz W. Bacterial ghosts: non-living candidate vaccines. J Biotechnol. 1996 Jan 26; 44(1-3):161-70.
57. Utsalo SJ, Eko FO, Antia-Obong OE, Nwaigwe CU. Aeromonads in acute diarrhoea and asymptomatic infections in Nigerian children. Eur J Epidemiol. 1995 Apr; 11(2):171-5.
58. Eko FO, Hensel A, Bunka S, Lubitz W. Immunogenicity of Vibrio cholerae ghosts following intraperitoneal immunization of mice. Vaccine. 1994 Nov; 12(14):1330-4.
59. Eko FO, Szostak MP, Wanner G, Lubitz W. Production of Vibrio cholerae ghosts (VCG) by expression of a cloned phage lysis gene: potential for vaccine development. Vaccine. 1994 Oct; 12(13):1231-7.
60. Eko FO, Udo SM, Antia-Obong OE. Epidemiology and spectrum of vibrio diarrheas in the lower cross river basin of Nigeria. Cent Eur J Public Health. 1994 Jun; 2(1):37-41.
61. Utsalo SJ, Eko FO, Antia-Obong EO. Features of cholera and Vibrio parahaemolyticus diarrhoea endemicity in Calabar, Nigeria. Eur J Epidemiol. 1992 Nov; 8(6):856-60.
62. Eko FO, Utsalo SJ. Antimicrobial resistance trends of shigellae isolates from Calabar, Nigeria. J Trop Med Hyg. 1991 Dec; 94(6):407-10.
63. Eko FO, Utsalo SJ. Occurrence of Plesiomonas shigelloides--associated diarrhoea in Calabar, Nigeria. East Afr Med J. 1991 Jul; 68(7):562-6.
64. Utsalo SJ, Eko FO, Antia-Obong OE. Cholera and Vibrio parahaemolyticus diarrhoea endemicity in Calabar, Nigeria. West Afr J Med. 1991 Apr-Jun; 10(2):175-80.
65. Epoke J, Eko F, Mboto CI. Vaccinated versus unvaccinated children: how they fare in first five years of life. Trop Geogr Med. 1990 Apr; 42(2):182-4.
66. Eko FO, Utsalo SJ. Comparative study of the prevalence and clinical profiles of diarrheas due to Aeromonas and other enteric pathogens. J Hyg Epidemiol Microbiol Immunol. 1990; 34(2):183-9.
67. Eko FO, Utsalo SJ. Characterization and significance of Aeromonas spp. isolated from diarrhoeic stools in Nigeria. J Trop Med Hyg. 1989 Apr; 92(2):97-101.

Research Resources icon

Funding Opportunities icon

Browse active NIH & NSF funding opportunities, requests for applications (RFAs), and program announcements (PAs)

Publications Timeline

Top MeSH Keywords

Tree Map of Keyword Semantic Groups (Categories)

Left-click a node to move down the tree, right-click the graph to move back up the tree

Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile:
Last Name
Chlamydia Infections
Chlamydia trachomatis
Bacterial Vaccines
Vibrio cholerae
See all (314) keywords
See all (16) people See all (60) people

RTRN Collaboration and Professional Networking Feedback